Arcturus Therapeutics Holdings Inc. (ARCT)

Market Cap	236.76M -31.6%
Revenue (ttm)	82.03M -46.1%
Net Income	-65.78M
EPS	-2.40
Shares Out	28.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	193,684
Open	8.30
Previous Close	8.22
Day's Range	8.19 - 8.43
52-Week Range	5.85 - 24.17
Beta	2.44
Analysts	Buy
Price Target	27.70 (+232.53%)
Earnings Date	May 11, 2026

About ARCT

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In additi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 111
• Stock Exchange: NASDAQ
• Ticker Symbol: ARCT
• Website: https://arcturusrx.com

Financial Performance

In 2025, ARCT's revenue was $82.03 million, a decrease of -46.14% compared to the previous year's $152.31 million. Losses were -$65.78 million, -18.73% less than in 2024.

Analyst Summary

According to 11 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price target is $27.7, which is an increase of 232.53% from the latest price.

Price Target

$27.7

(232.53% upside)

Analyst Consensus: Buy